News

Filter

Current filters:

None

10 to 19 of 96157 results

GPhA calls for feedback and dialogue on US generic legislation

GPhA calls for feedback and dialogue on US generic legislation

18-09-2014

The US Generic Pharmaceutical Association (GPhA) has identified areas in which the Generic Drug User…

GenericsGPhALegalRegulationUSA

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

AACR report calls for US cancer funding to be a national priority

AACR report calls for US cancer funding to be a national priority

18-09-2014

Declining budgets have slowed the pace of research into cancer, according to a new report from the American…

AbraxaneCyramzaFinancialGazyvaImbruvicaNexavarOncologyPharmaceuticalResearchTafinlarUSAZydelig

UK NICE consults on draft guidance for hepatitis C drug Olysio

UK NICE consults on draft guidance for hepatitis C drug Olysio

18-09-2014

In draft guidance published today UK drugs watchdog the National Institute for Health and Care Excellence…

Anti-viralsJanssenJohnson & JohnsonOlysioPharmaceuticalPricingRegulationUK

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

Cardiorentis enters into financing agreement with HealthCare Royalty Partners to fund Ularitide

17-09-2014

Privately-held Swiss pharma company Cardiorentis AG has entered into a €45 million ($58.3 million)…

Cardio-vascularCardiorentisFinancialPharmaceuticalSwitzerlandUlaritide

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

17-09-2014

US biotech major Gilead Sciences has announced disappointing results from a Phase II study evaluating…

BiotechnologyGilead SciencesOncologyResearchsimtuzumabUSA

Merck & Co out-licenses tildrakizumab to Sun Pharma

Merck & Co out-licenses tildrakizumab to Sun Pharma

17-09-2014

US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker…

DermatologicalsGlobalLicensingMerck & CoPharmaceuticalSun Pharmaceuticalstildrakizumab

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

10 to 19 of 96157 results

Back to top